| May 8 |
enVVeno Medical Reports First Quarter 2024 Financial Results and Provides Corporate Update
|
| Apr 24 |
Positive 11 Month Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical's VenoValve(R) Pivotal Trial to be Presented Today at the 46th Annual Charing Cross Symposium
|
| Apr 16 |
New Topline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024
|
| Mar 15 |
enVVeno Medical to Participate in the Virtual Investor Lunch Break: The enVVeno Opportunity
|
| Mar 6 |
enVVeno: The Road To Approval Seems Open From Here On
|
| Mar 6 |
Positive Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical’s VenoValve(R) Pivotal Trial to be Presented Today at the VENOUS2024 American Venous Forum Annual Meeting
|
| Mar 3 |
Companies Like enVVeno Medical (NASDAQ:NVNO) Are In A Position To Invest In Growth
|
| Mar 1 |
enVVeno Medical reports FY results
|
| Feb 29 |
enVVeno Medical Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
|
| Feb 20 |
Topline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the VENOUS2024 American Venous Forum Annual Meeting on March 6, 2024
|
